Insider Cluster (2 insiders) ·Filed Apr 15, 2026

GILD

GILEAD SCIENCES, INC.
BEARISH
Impact 6/10
Horizondays Processed5mo ago
Insider cluster: 2 insiders, $846K total
Actionable Insight ▼ Bearish

Traders should monitor for follow-up filings or commentary, as coordinated C-suite selling may signal reduced confidence in near-term prospects, especially if not part of a pre-arranged plan. Compare against historical Form 4 patterns to assess whether this is routine or atypical.

DirectionBearish
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
GILD ▼ -3.41% at T+60d
SHORT call ✓ call won +3.41% · α vs SPY +10.80% · entry $139.60 → $134.84
Entry anchored
Apr 14, 03:59 PM ET
via exchange tick
T+1d
-0.80%
call +0.80% · α +1.05%
$138.49
settled 6mo ago
T+5d
-4.83%
call +4.83% · α +6.47%
$132.85
settled 5mo ago
T+20d
-3.34%
call +3.34% · α +9.38%
$134.94
settled 5mo ago
T+60d
-3.41%
call +3.41% · α +10.80%
$134.84
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Two Gilead Sciences executives — the CFO and Chief Communications Officer — each sold 3,000 shares in open-market transactions on April 15, 2026, totaling $846,000. The sales represent a modest but notable insider selling cluster by C-suite executives, occurring within a single day.

Key Financial Metrics

Direction
selling
Total Value
$845.8K
Insiders
2

Key Facts

  • CFO Andrew D. Dickinson sold 3,000 shares for $422,880 in an open-market transaction.
  • Chief Communications Officer Johanna Mercier sold 3,000 shares for $422,880 in an open-market transaction.
  • Both sales occurred on April 15, 2026, at $140.96 per share.
  • Total value of the cluster: $845,760.

Financial Impact

$845,760 in open-market sales by two C-suite executives

insider ownershipmarket sentiment

Risk Factors

  • Perception of insider skepticism, particularly given participation by CFO
  • Potential for negative market reaction if no public rationale is provided

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
79% bullish (39 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-GILD-1776379349175
16 reports for GILD
Performance horizon
80% Hit rate 4 of 5 directional calls best @ T+60▲ +16.72%Jul 6, 2026
Filters
Rows
Reports for GILD — sortable, filterable
TypeNow
Sep 2, 2026
4w ago
Insider Cluster
NEUTRAL ★ 2/10
$149.61 $149.05▼ −0.37%▼ −0.04%$144.74 (−3.26%)
Aug 27, 2026
5w ago
Insider Cluster
NEUTRAL ★ 2/10
$145.68 $152.21▲ +4.48%▲ +4.22%$144.74 (−0.65%)
Aug 21, 2026
5w ago
Insider Cluster
NEUTRAL ★ 3/10
$146.74 $152.67▲ +4.04%▲ +2.73%$144.74 (−1.36%)
Aug 18, 2026
6w ago
Insider Cluster
NEUTRAL ★ 2/10
$147.60 $150.89▲ +2.23%▲ +4.18%$144.74 (−1.94%)
Aug 18, 2026
6w ago
Court Ruling
BULLISH ★ 7/10
$143.44 $147.68▲ +2.96%▲ +4.27%$144.74 (+0.91%)
Aug 13, 2026
7w ago
Court Ruling
BULLISH ★ 6/10
$138.14 $143.72▲ +4.04%▲ +5.79%$144.74 (+4.78%)
Aug 6, 2026
8w ago
S-3ASR
NEUTRAL ★ 2/10
$133.21 $151.00▲ +13.35%▲ +13.75%$144.74 (+8.66%)
Jul 21, 2026
10w ago
ANALYST-DOWNGRADE
BEARISH ★ 4/10
$130.28 $143.44▼ −10.10%▼ −7.54%$144.74 (−11.10%)
Jul 16, 2026
11w ago
Insider Cluster
NEUTRAL ★ 2/10
$134.28 $138.33▲ +3.02%▼ −1.43%$144.74 (+7.79%)
Jul 6, 2026
12w ago
ANALYST-UPGRADE
BULLISH ★ 3/10
$129.61 $130.21▲ +0.46%▲ +1.03%$144.74 (+11.67%)
Showing 10 of 16

US Market Status

Market Closed — Opens Mon (65h 2m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Apr 16, 2026